International researchers are looking into ways to promote better human health by improving gastrointestinal health, outlining their findings in the recently published ‘A core-shell multi-drug platform to improve gastrointestinal tract microbial health using 3D printing.’
3D printing is connected with the medical field today in countless ways as researchers and manufacturers continue to innovate, encouraged by the potential for an infinite number of designs to allow for medical models and instruments, devices such as implants and prosthetics, and accompanying software, hardware, and materials. In this study, the authors branch out into a more unique and complex area of medicine, creating core-shell structure fibers via electrohydrodynamic 3D printing.
These types of fibers can be fabricated in a variety of shapes and sizes, and have to ability to deliver and release drugs; in fact, the researchers state that the biphasic drug release profile in simulated intestinal fluid offers ‘a burst release within the first 12 h and a slower sustained release up to 72 h.’
Bacteria living in the gastrointestinal tract can be both good and bad. It may be responsible for providing vitamins, nutrients, and digestion, but in turn, can also be hazardous to human health when there is an imbalance—causing a range of health issues from obesity to diabetes, and even worse—cancer. With suitable probiotics, however, and resulting gastrointestinal health, many patients see their health improve overall.
The fibrous membranes used in this study were successful in showing the potential for improved gastrointestinal health, coupled with the electrohydrodynamic (EHD) 3D printing. The authors chose this technique due to the following advantages:
- Enabling of micro to nanoscale fiber engineering
- Control and development of complex structures
- Precise printing of stacked and aligned fibers
- Personalized drugs can be created
“… cellulose acetate (CA) and polyacrylic resin II (PRII) were used as excipient materials of enteric-specific medicine due to its good biocompatibility , nontoxicity , and pH dependent  characteristics,” explained the authors. “The CA encapsulating stachyose (CA-STA) was used as shell while PRII loading proteoglycan (PRII-PRO) was used to form the core of the fibrous structures.”
The EHD printer was comprised of:
- Programmable X-Y-Z movement stage
- High power voltage supply
- Two syringe pumps
- Coaxial stainless-steel nozzle (inner and outer needles)
For the study, the authors created a square grid, semi-circle, and a whole circle using 10-layer deposition with an average thickness of 61.5 ± 2.6 μm. The printed fibers were examined with optical microscopy, as the team replaced PRO with Rhodamine B into the loaded PRII-core layer. Diameters of the inner and outer shells were 10.8 ± 3.7 μm and 61.2 ± 6.2 μm.
The enteric capsule, tested a delivery system for oral drugs, was comprised of the sample fibers.
“The in vitro drug release was carried using PBS solution (pH = 7.4) to mimic intestinal fluid,” explained the researchers. “The LC for STA and PRO was 3.67 ± 0.1% and 1.1 ± 0.02%, respectively; and the EE was 90.3 ± 1.7% and 95.3 ± 0.5%, respectively. This confirms each drug was efficiently loaded into outer layer and inner layer, respectively.”
For each sample, thickness was measured before tensile testing was performed, noted respectively for the square, semi-circle, and whole-circle membranes at 64.4 ± 2.6 μm, 61.9 ± 4.2 μm, and 58.1 ± 2.5 μm.
Because zig-zag patterns were prominent in the membrane sandwich structure, the research team notes them as critical elements in deciding mechanical properties of the 3D printed samples. Tensile strengths and broken strains increased, however, as the circle proportion increased—attributed to circular fibers transforming into a straight line when under the pressure of tensile force. Maximum tensile strength was also noted as ‘greater than 0.22 MPa,’ the gastrointestinal pressure of in humans.
“The printed drug-loaded membrane possessed good biocompatibility on L929 cells and excellent improvement effects on Bifidobacterium bifidum, alongside adequate inhibition effects on E. coli. Compared to the control, the proliferation ratio of Bifidobacterium bifidum can be raised to 294.2% and 242.7%, respectively, at the treatment of 0.1 g PRII-STA/CA-PRO and PRII-PRO/CA-STA,” concluded the researchers.
“The inhibition effects on E. coli was 37.0% and 27.5%, at the treatment of 0.1 g PRII-STA/CA-PRO and PRII-PRO/CA-STA, respectively. This result confirmed the feasibility of improving proliferation of probiotics (Bifidobacterium bifidum) combining with inhibiting growth of pathogenic (E. coli) in a single dosage for using dual drug loading. The core–shell structures developed here can be extremely advantageous in efficient therapy for gastrointestinal conditions.”
What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.[Source / Images: ‘A core-shell multi-drug platform to improve gastrointestinal tract microbial health using 3D printing’]
You May Also Like
An Unforgettable AMUG | 3D Printing Leadership Redefined in 2021
“Please wear a mask in public spaces,” the Hilton Hotel lobby signage makes it pretty clear upon arrival that they want their guests to feel comfortable and safe while on...
3D Systems Acquires Bioprinting and Simulation Firms Allevi and Additive Works
When we spoke to 3D Systems (NYSE: DDD) CEO Jeff Graves on the 3DPod, he talked of a strategic refocus and the possibility of future acquisitions. On the podcast, Jeff...
3D Printed Artificial Leaves Could Generate Oxygen on Mars
Researchers at the Delft University of Technology (TU Delft) have developed a method for bioprinting algae to create living, photosynthetic materials that are tough and resilient. The resulting study, published...
Made in SPACs: Redwire to Take Space 3D Printing to NYSE via SPAC
You might be growing tired of the neologism “SPACtacular” by now, but it’s hard to avoid when there are new merger deals with special purpose acquisition companies (SPACs) occurring in...
View our broad assortment of in house and third party products.